Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myelomonocytic leukemia: lost in classification?

David T Bowen1

  • 1Department of Hematology, Leeds General Infirmary, UK. dt.bowen@dundee.ac.uk

Hematological Oncology
|September 9, 2005
PubMed
Summary

Chronic myelomonocytic leukemia (CMML) is a distinct myeloid malignancy characterized by ineffective hematopoiesis and RAS pathway activation. Current therapies are limited, highlighting the need for better understanding and targeted treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome.

Blood·2021
Same author

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

The Lancet. Haematology·2020
Same author

SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS.

Blood·2020
Same author

Telomere length is an independent prognostic marker in MDS but not in de novo AML.

British journal of haematology·2017
Same author

Impact of socioeconomic status on disease phenotype, genomic landscape and outcomes in myelodysplastic syndromes.

British journal of haematology·2016
Same author

Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.

Blood·2015

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Chronic myelomonocytic leukemia (CMML) is a distinct myeloid malignancy, previously grouped with myelodysplastic (MDS) and myeloproliferative (MPD) disorders.
  • CMML presents unique clinical features, including ineffective hematopoiesis (anemia, thrombocytopenia) and a tendency for monocyte count increase.
  • Biological pathways differ from MPD, with frequent RAS pathway activation in CMML versus STAT pathway activation in MPD.

Purpose of the Study:

  • To delineate the distinct characteristics of CMML compared to MDS and MPD.
  • To explore the underlying biological mechanisms driving CMML.
  • To underscore the limitations of current CMML therapies and the need for novel approaches.

Main Methods:

  • Review and synthesis of existing literature on CMML classification, clinical presentation, and biological underpinnings.

Related Experiment Videos

  • Comparative analysis of CMML with MDS and MPD based on hematopoiesis, progenitor cell behavior, and molecular pathways.
  • Evaluation of current therapeutic strategies and their outcomes.

    • Main Results:

    • CMML is now classified separately by WHO, acknowledging its unique disease spectrum.
    • Key differences include ineffective hematopoiesis and distinct molecular pathway activation (RAS in CMML, STAT in MPD).
    • Current treatments primarily focus on supportive care and managing myeloproliferation; intensive chemotherapy and stem cell transplantation offer limited curative potential.

    Conclusions:

    • CMML represents a unique myeloid malignancy with specific clinical and biological features.
    • Existing therapies for CMML are largely unsatisfactory, necessitating further research.
    • A deeper understanding of CMML's biology is crucial for developing targeted therapies, similar to advancements in other MPDs.